Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about a class action lawsuit with a lead plaintiff deadline of February 9, 2026 [1]. Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by February 9, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5]. - It is claimed that Integer mischaracterized its EP devices as a long-term growth driver for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while publicizing sales growth and market position [4]. - Contrary to public assurances, demand and revenue from Integer's electrophysiology products had reportedly fallen sharply [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' estimates [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, citing slower adoption of two of its electrophysiology devices [6]. - Following this announcement, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about a class action lawsuit with a lead plaintiff deadline of February 9, 2026 [1]. Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by February 9, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - The lawsuit asserts that the positive statements made by the defendants lacked a reasonable basis, leading to investor damages when the true details were revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business operations and sales performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint claims that Integer overstated its competitive positioning in the market [3]. - It alleges that the company experienced undisclosed deterioration in sales of its electrophysiology devices [3]. - The company mischaracterized the key drivers of its growth, leading to a significant stock price drop of $35.22 per share, a decline exceeding 32% in a single day following the announcement of reduced sales guidance [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a class action lawsuit due to misleading statements regarding its business performance and sales projections [4]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [2]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. - Sales of three new products, including two electrophysiology devices, were expected to decline in 2026, with slower market adoption than forecasted [2]. Stock Market Reaction - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Lawsuit Details - The class action lawsuit alleges that Integer made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4]. - Specific allegations include overstating its competitive position in the electrophysiology manufacturing market and mischaracterizing its EP devices as long-term growth drivers [4]. Legal Action - Investors who purchased Integer common stock during the class period (July 25, 2024, to October 22, 2025) have until February 9, 2026, to file a lead plaintiff motion in the class action [1][5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation, alleging misrepresentations regarding its market position and overstated demand for its electrophysiology devices [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired Integer common stock between July 25, 2024, and October 22, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Integer and certain senior officers [3]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiff must file necessary documents by February 9, 2026 [5]. - Serving as a lead plaintiff allows representation of other class members in directing the litigation, but it is not required to share in any potential recovery [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts regarding its business performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers, leading to a significant decline in stock price following the revelation of these issues [3]. Group 3: Impact of Disclosures - On October 23, 2025, Integer reduced its sales guidance and disclosed an expected sales decline, resulting in a stock price drop of $35.22 per share, which is over 32% in a single trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Performance and Guidance - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026 [6]. - The announcement led to a drastic decline in Integer's stock price, dropping $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Integer Holdings Corporation will host a conference call to discuss its financial results and business highlights for Q4 and the full year of 2025 on February 19, 2026 [1] Group 1: Conference Call Details - The conference call is scheduled for February 19, 2026, at 8 a.m. CT / 9 a.m. ET [1] - An audio replay of the conference call will be available for seven days, accessible by dialing (800) 770-2030 or (609) 800-9909 with Conference ID 3120125 [2] - The call will also be available live and via archived replay on the Investor Relations section of the Integer website [2] Group 2: Company Overview - Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations (CDMO) globally, serving markets such as cardiac rhythm management and neuromodulation [4] - The company aims to enhance patient lives by providing innovative, high-quality products and solutions [4] - Integer's brands include Greatbatch Medical and Lake Region Medical [4]